We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Retrospective Comparison of Bortezomib-containing Regimens with Vincristine–Doxorubicin–Dexamethasone (VAD) as Induction Treatment Prior to Autologous Stem Cell Transplantation for Multiple Myeloma.
- Authors
Eom, Hyeon-Seok; Min, Chang-Ki; Cho, Byung-Sik; Lee, Seok; Lee, Jong-Wook; Min, Woo-Sung; Kim, Chun-Choo; Kim, Myungshin; Kim, Yonggoo
- Abstract
Objective: Patients with multiple myeloma (MM) achieving high-quality responses, defined as a complete response (CR) and a very good partial response (VGPR) after transplant, benefit from high-dose therapy followed by autologous stem cell transplantation (ASCT). Induction pre-transplantation treatment with vincristine, doxorubicin and dexamethasone (VAD) is currently being replaced by new targeted agents with high anti-myeloma activity. The use of these novel agents may increase the CR + VGPR rate before ASCT, which may improve post-transplantation responses and survival.
- Publication
Japanese Journal of Clinical Oncology, 2009, Vol 39, Issue 7, p449
- ISSN
0368-2811
- Publication type
Article
- DOI
10.1093/jjco/hyp046